Ascendiant Capital Markets Predicts Pro-Dex Q1 Earnings

Pro-Dex, Inc. (NASDAQ:PDEX) – Equities researchers at Ascendiant Capital Markets issued their Q1 2027 earnings per share estimates for Pro-Dex in a report released on Monday, May 11th. Ascendiant Capital Markets analyst E. Woo forecasts that the medical instruments supplier will post earnings of $0.66 per share for the quarter. Ascendiant Capital Markets currently has a “Buy” rating and a $70.00 target price on the stock. Ascendiant Capital Markets also issued estimates for Pro-Dex’s Q2 2027 earnings at $0.69 EPS, Q3 2027 earnings at $0.74 EPS, Q4 2027 earnings at $0.70 EPS and FY2027 earnings at $2.78 EPS.

Pro-Dex (NASDAQ:PDEX) last issued its quarterly earnings data on Thursday, April 30th. The medical instruments supplier reported $1.20 earnings per share (EPS) for the quarter, topping the consensus estimate of $0.62 by $0.58. The business had revenue of $19.95 million during the quarter, compared to the consensus estimate of $17.90 million. Pro-Dex had a return on equity of 22.78% and a net margin of 16.08%.

Separately, Weiss Ratings reiterated a “hold (c+)” rating on shares of Pro-Dex in a research report on Friday, May 1st. One analyst has rated the stock with a Buy rating and one has issued a Hold rating to the company’s stock. Based on data from MarketBeat.com, Pro-Dex currently has a consensus rating of “Moderate Buy” and a consensus target price of $70.00.

Pro-Dex Stock Performance

Shares of NASDAQ PDEX opened at $56.50 on Wednesday. The company has a current ratio of 3.67, a quick ratio of 2.14 and a debt-to-equity ratio of 0.32. The stock has a 50 day simple moving average of $50.45 and a 200-day simple moving average of $42.47. The company has a market cap of $180.24 million, a PE ratio of 15.61 and a beta of -0.12. Pro-Dex has a 12-month low of $23.47 and a 12-month high of $61.62.

Hedge Funds Weigh In On Pro-Dex

Hedge funds and other institutional investors have recently made changes to their positions in the business. Punch & Associates Investment Management Inc. raised its holdings in Pro-Dex by 42.1% during the third quarter. Punch & Associates Investment Management Inc. now owns 48,608 shares of the medical instruments supplier’s stock worth $1,645,000 after purchasing an additional 14,408 shares in the last quarter. Osaic Holdings Inc. raised its holdings in Pro-Dex by 44.8% during the fourth quarter. Osaic Holdings Inc. now owns 11,434 shares of the medical instruments supplier’s stock worth $440,000 after purchasing an additional 3,540 shares in the last quarter. LPL Financial LLC bought a new stake in Pro-Dex during the fourth quarter worth approximately $228,000. First Trust Advisors LP bought a new stake in Pro-Dex during the fourth quarter worth approximately $222,000. Finally, Quadrature Capital Ltd bought a new stake in Pro-Dex during the fourth quarter worth approximately $220,000. 15.28% of the stock is currently owned by institutional investors and hedge funds.

About Pro-Dex

Pro-Dex, Inc is a designer and manufacturer of precision drive systems and fluid management products serving the dental, medical, industrial and energy markets. The company specializes in high-speed, brushless micromotors and controllers, as well as pneumatic and fluid control devices, providing both standard and custom-engineered solutions for original equipment manufacturers.

Its product portfolio includes high-speed dental handpieces, turbine systems, rotary and reciprocating micro-drives, along with integrated fluid delivery systems.